Compare Illumina, Inc. (ILMN) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Shell PLC — how do they compare? Illumina, Inc. trades at $191.33 (market cap $29.12B), while Shell PLC trades at $90 (market cap $250.44B). The key difference: Shell PLC is far larger — about 8.6× Illumina, Inc.'s market cap, and Shell PLC pays a 3.45% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | SHEL | |
|---|---|---|
Market Cap | $29.12B | $250.44B |
Sector | Health | Energy |
52-Week High | $205.10 | $94.15 |
52-Week Low | $91.00 | $70.31 |
Enterprise Value | $30.48B | $292.14B |
Dividend Yield | — | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $191.79, up 2.04% today, with a neutral technical signal and strong fundamental recovery. The stock shows bullish moving averages but faces resistance near $194. Recent earnings beats and a return to profitability in 2025, with $850M net income, highlight operational turnaround. Revenue remains stable around $4.3B, supported by robust gross margins of 66.38%.
Outlook is positive with analyst consensus Buy rating and $201.58 price target, though high P/E of 35.98 poses valuation risk. Key opportunities include sequencing demand and AI partnerships, while risks involve debt levels and competitive pressures. Institutional activity is mixed, with some funds increasing stakes amid earnings momentum.
Shell (SHEL) trades at $90.15, up 0.22% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.60. Recent Q2 2026 earnings beat estimates with EPS of $3.52 versus $3.23 expected, driven by higher oil prices and strong operational performance. The company maintains solid profitability with a net income margin of 8.76% and ROE of 14.35%, while cash flow from operations reached $42.86B in 2025.
Outlook is positive due to undervaluation (P/E of 10.01), rising oil prices, and strategic asset sales, but risks include commodity volatility and geopolitical tensions affecting energy markets. With 69% of analysts rating it Buy and institutional support, SHEL offers growth potential, though investors should monitor debt levels and global energy demand shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
